A late-stage clinical trial designed to see if Xtandi in addition to Zytiga along with a steroid worked any better than either of these drugs separately (combining them v sequencing them) in men with advanced prostate cancer whose disease had worsened it was concluded that the combination was not superior to the individual drugs. This [...]
Dr. Steve Freedland, from Cedar Sinai conducted a controlled, randomized clinical study that evaluated the efficacy of an extremely low carbohydrate diet on the side effects of hormone therapy (ADT). The study showed that an extreme diet has a positive impact on many of the side negative effects as well as causing significant weight loss [...]
We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM [...]
Clinical trials are the main stream of developing and then getting necessary approvals for drugs to be able to make it to market. Drug companies, like every other company and every individual want only to have successes. We all also have egos and when there is a failure we often prefer to bury that information [...]
In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]